Monoclonal antibody · developed by MacroGenics
Teplizumab Curtailed Herold is a dosing regimen of teplizumab given intravenously, with full-dose treatment for 6 days followed by 8 days of placebo, repeated at Week 26. It is studied in type 1 diabetes mellitus.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00920582 | Phase 3 | Type 1 Diabetes Mellitus | Terminated | MGNX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Type 1 Diabetes Mellitus
Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.
See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGNX catalysts and pipeline →